Latest Health News

Island Pharmaceuticals has submitted a detailed briefing to the FDA aiming to accelerate approval of its antiviral Galidesivir for Marburg virus under the Animal Rule, with feedback expected by November.

Synlait Milk Limited reports a modest profit turnaround in FY25 and announces a major sale of its North Island assets to Abbott, aiming to reduce debt and sharpen its focus on core operations.

Synlait Milk Limited has completed a $350 million refinancing package with a strong banking syndicate, featuring amended financial covenants for FY26 and maintaining key shareholder support.

Bod Science Limited has reported a notable profit turnaround for FY2025, driven by medicinal cannabis sales growth, while navigating a complex Deed of Company Arrangement and a proposed backdoor listing with Biortica Agrimed Limited.

NIB Holdings Limited has updated its dividend details, declaring a fully franked ordinary dividend of AUD 0.16 per share for the first half of FY2025 and revising the Dividend Reinvestment Plan price to AUD 7.5154.

Schaffer Corporation has pulled its first-half profit forecast for its Automotive Leather division following a major cyber-attack on Jaguar Land Rover that halted production. The incident casts uncertainty over short-term sales and profitability.

Caravel Minerals has released its first comprehensive Sustainability Report for fiscal 2025, detailing ambitious ESG initiatives and a clear roadmap toward net-zero emissions for its Caravel Copper Project in Western Australia.

Murray Cod Australia Limited reports a profitable FY25 with a significant biomass increase and completes a $17 million capital raise to fund infrastructure and market expansion ahead of a commercial inflection in FY26.

Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.

AssetOwl Limited has had over $700,000 of debt forgiven by two lenders, significantly reducing its borrowings and strengthening its financial position.

Range International has completed the first tranche of a capital raise, securing A$1.58 million to support growth in Indonesia and the Philippines while reducing debt.

Recce Pharmaceuticals has initiated patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, targeting a significant market with high diabetes prevalence. Interim results expected in early 2026 could accelerate regulatory approval and commercial launch.